Citius Oncology reports FY 2025 net loss of $24.8M; launches LYMPHIR in U.S.

CITIUS ONCOLOGY, INC.

Net loss of $24.8M ($0.34 per share) vs $21.1M ($0.31) in FY 2024, driven by pre-commercial investment.
Cash and equivalents $3.9M as of Sep 30, 2025; raised $36M in three financings post- and intra-year.
LYMPHIR launched in U.S. Dec 2025; distribution agreements with top three wholesalers secured.
International access via Named Patient Programs in 19 markets; collaboration with Verix for AI-driven commercial targeting.
R&D expense $6.4M (up from $4.9M); G&A $8.8M ($8.1M prior); stock-based comp $8.3M ($7.5M).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.